William Villanueva-Bosque, MD
Pulmonary Disease · Arecibo, PRNPI 1871595694
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,600 of the $67,368 with a category attached, or 91.4%. GSK accounts for 91.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $16,935 and has fallen 96.1% since, to $659 in 2025. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $575.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$62K
- Viiv Healthcare Company$3K
- AstraZeneca$729
- Genentech USA, Inc.$367
- Boehringer Ingelheim$275
- Merck$139
- plus $549 from 9 others
What the payments were for
- Speaking & faculty fees$61,60091%
- Travel & lodging$1,4982%
- Food & beverage$4,2446%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 82 | $61,909 |
| Viiv Healthcare Company | 1 | $3,400 |
| AstraZeneca | 11 | $729 |
| Genentech USA, Inc. | 6 | $367 |
| Boehringer Ingelheim | 5 | $275 |
| Merck | 2 | $139 |
| Bayer | 1 | $125 |
| United Therapeutics Corporation | 2 | $112 |
| Sanofi | 1 | $105 |
| Jazz Pharmaceuticals Inc. | 1 | $63 |
| KCI USA, Inc. | 1 | $49 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Boston Scientific | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Mylan LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$40,765
- ANORO ELLIPTA$4,911
- ANORO$1,365
- TEZSPIRE$250
- NUCALA$200
- Esbriet$125
- Adempas$125
- AREXVY$125
- DALIRESP$120
- DUPIXENT$105
How this compares
$67,368 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 71 | $930,252 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 444 | $301,739 |
| Breo ElliptaFluticasone/Vilanterol | 450 | $186,698 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 292 | $148,873 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 507 | $131,375 |
| Fluticasone Propionate HfaFluticasone Propionate | 538 | $115,244 |
| Qvar RedihalerBeclomethasone Dipropionate | 371 | $89,031 |
| Spiriva RespimatTiotropium Bromide | 164 | $87,319 |
| SymbicortBudesonide/Formoterol Fumarate | 354 | $83,876 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 170 | $83,132 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 124 | $81,602 |
| TezspireTezepelumab-Ekko | 11 | $44,978 |
| Wixela InhubFluticasone Propion/Salmeterol | 330 | $44,499 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 784 | $36,253 |
| Spiriva HandihalerTiotropium Bromide | 53 | $27,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $275 | $1,166,444527 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $61,909 | $576,4381,086 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Tezspire, Bevespi Aerosphere, Pulmicort Flexhaler | $729 | $222,697523 claims |
| MerckLagevrio (Eua) | $139 | $13,33115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Arecibo
- Jahaira Serrano DominguezArecibo$102K
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Domingo Chardon FelicianoPonce$45K
- Joel Nieves ScharonSan Juan$43K
- George FahedPonce$16K
- Luis Gerena MontanoSan Juan$15K
- Rafael Franjul JuliaoSan Juan$15K
- Roberto Martinez QuintanaSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.